iRadimed Corp. (NASDAQ:IRMD) traded down 3.7% during mid-day trading on Thursday . The company traded as low as $18.47 and last traded at $18.56, with a volume of 60,690 shares changing hands. The stock had previously closed at $19.27.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of iRadimed Corp. from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 5th. Roth Capital reduced their price target on shares of iRadimed Corp. from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, April 4th.

The stock’s 50 day moving average price is $20.66 and its 200-day moving average price is $18.54. The company has a market capitalization of $202.60 million and a P/E ratio of 27.83.

iRadimed Corp. (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, April 29th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.03. During the same period in the prior year, the company earned $0.17 EPS. The business had revenue of $8.96 million for the quarter, compared to the consensus estimate of $9.05 million. iRadimed Corp.’s quarterly revenue was up 28.6% on a year-over-year basis. Analysts anticipate that iRadimed Corp. will post $0.89 earnings per share for the current year.

In related news, Director Monty K. Allen sold 2,100 shares of the business’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $20.44, for a total transaction of $42,924.00. Following the completion of the sale, the director now owns 4,375 shares of the company’s stock, valued at approximately $89,425. The sale was disclosed in a legal filing with the SEC, which is available through this link.

An institutional investor recently raised its position in iRadimed Corp. stock. GSA Capital Partners LLP increased its position in iRadimed Corp. (NASDAQ:IRMD) by 174.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,203 shares of the company’s stock after buying an additional 31,901 shares during the period. GSA Capital Partners LLP owned approximately 0.45% of iRadimed Corp. worth $1,407,000 as of its most recent filing with the SEC.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.